The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms [4]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 4, 2003, Pages 419-420

  Baird, Pryor ^a  

^a Mental Health Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; NORCLOMIPRAMINE; OLANZAPINE; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; AGGRESSION; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HOSPITALIZATION; HUMAN; LETTER; MALE; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; SIDE EFFECT; STEADY STATE;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARBAMAZEPINE; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SCHIZOPHRENIA;

EID: 0042133394     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000085420.74359.29     Document Type: Letter

References (14)

1. Harvey AT, Preskorn SH. Cytochrome p450 enzymes: interpretations of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996;16:345-355.
2. Kahn EM, Schulz SC, Perel JM, et al. Change in haloperidol level due to carbamazepine: a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990;10:54-57.
3. Bernstein JG. Handbook of Drug Therapy in Psychiatry. New York: Mosby; 1995:344.
4. Jachna J, Lane R, Gelenberg A. Psychopharmacology. In: Rundell J, Wise M, eds. Textbook of Consultation - Liaison Psychiatry. Washington, DC: American Psychiatric Press; 1996:958-1005.
5. Brown R, Golstein M, Niaura R, et al. Nicotine dependence: assessment and management. In: Stoudemire A, Fogel B, eds. Psychiatric Care of the Medical Patient. New York: Oxford University Press; 1993:877-901.
6. Ghaemi SN, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. Primary Psychiatry. 2002;9:55-59.
7. Physicians Desk Reference. Montvale, NJ: Medical Economics Data Production Company; 2002.
8. DeVane CL, Nemeroff CB. 2002 guide to psychotropic drug interactions. Primary Psychiatry. 2002;9:36-70.
9. Steffans DC, Krishnan KR, Doraiswamy PM. Psychotropic Drug Interactions [1997 pocket reference]. New York: MBL Communications; 1997:8-30.
10. Tollefson GD. Selective serotonin reuptake inhibitors. In: Schatzberg A, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:168.
11. Brickley P, Meltzer H. Treatment of schizophrenia. In: Schatzberg A, Nemeroff CB, eds. The American Psychiatric Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:632.
12. Preskorn SC, Burke M, Fast G. Therapeutic drug monitoring. Psychiatr Clin North Am. 1996;16:611-641.
13. Callahan A, Fava M, Rosenbaum J. Drug interactions in psychiatry. Psychiatr Clin North Am. 1993;16:647-671.
14. Sachs G. The Treatment of Bipolar Disorders. Lecture at Massachusetts General Hospital, Psychopharmacology Conference; October 16, 1998; Boston, MA.